arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

HARVARD BIOSCIENCE INC

HBIO
$8.46 ▼ -0.21 (-2.48%) at close
Industrials ·Laboratory Analytical Instruments ·USLaboratory Analytical Instruments
68 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

HARVARD BIOSCIENCE INC faces fundamental challenges with weakness in Profit Margin (%) and Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $38.3M
Dividend Yield —
Revenue Growth 11.1% ↗
Op. Margin -4.3% ↗
ROIC -2.2% ↗
FCF / Share $-0.08 ↗
Trailing P/E —
Price / Book 5.2x
FCF Yield —
Debt / Equity 4.94
info Valuation on last close. End-of-day price, Nov 5, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$22.73M
↑ +11.1% —
Net Income Profit after all expenses
$-2.91M
↓ -27.5% —
Operating Margin Operating profit as % of sales
-4.3%
↑ +23.9% 5th
FCF / Share Free cash flow per share
$-0.08
↑ +67.0% —
Long-Term Debt Long-term obligations
$36.68M
↑ +1.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability →
19
Financial Health ↑
18
Cash Quality ↑
19

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 18 years · 68 quarters